Immunotech Biopharm Ltd. announced that its indirect non-wholly owned subsidiary, Yongtai Beijing, has entered into an Entrustment Service Agreement with Tasly on 27 January 2026. Under the agreement, Yongtai Beijing will provide cell therapy processing services to Tasly. The company stated that the transaction is conducted in the ordinary and usual course of business, on normal commercial terms or better, and is expected to enhance the utilization of existing facilities and generate stable service income streams. The terms of the agreement, including the proposed annual caps, were deemed fair and reasonable by the company's board of directors.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunotech Biopharm Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260127-12002592), on January 27, 2026, and is solely responsible for the information contained therein.